Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Sino Biopharmaceutical Buys Hygieia Pharma for up to RMB 1.2 B, Adding siRNA Platform for Chronic Diseases

Fineline Cube Jan 15, 2026
Company Deals

Immvira Bio Files for Hong Kong IPO with Phase II Oncolytic Immunotherapy MVR-T3011

Fineline Cube Jan 15, 2026
Company Deals

Exegenesis Bio Files for Hong Kong IPO with AI-Powered Gene Therapy Pipeline

Fineline Cube Jan 15, 2026
Company Deals

QYuns’ QX030N Partner Caldera Raises $112.5 Million for IBD Bispecific

Fineline Cube Jan 15, 2026
Company Deals

NVIDIA and Eli Lilly Launch $1 Billion AI Co‑Innovation Lab to Transform Drug Development

Fineline Cube Jan 14, 2026
Policy / Regulatory

NHSA Releases NRDL Value Assessment Guidelines, Prioritizing 8 Drug Categories for Real‑World Evaluation

Fineline Cube Jan 15, 2026
Company Drug

J&J’s TECVAYLI Shows 71% PFS Reduction in Phase 3 MajesTEC‑9 for Multiple Myeloma

Fineline Cube Jan 15, 2026
Company Drug

Leads Biolabs’ Opamtistomig Secures FDA Fast Track for EP-NEC as First 4-1BB Bispecific

Fineline Cube Jan 15, 2026
Policy / Regulatory

Beijing Drafts Regulations for Internet Diagnosis and Treatment, Prohibits AI Prescriptions

Fineline Cube Aug 24, 2023

The Beijing Municipal Health Commission has released the “Implementation Measures for Internet Diagnosis and Treatment...

Company

Innovent Biologics Reports 20.6% YOY Revenue Growth in H1 2023 Financials

Fineline Cube Aug 24, 2023

China-based Innovent Biologics Inc., (HKG: 1801) has released its financial results for the first half...

Company Drug

Eli Lilly’s Retevmo Meets Primary Endpoint in Phase III Trial for RET-mutant Medullary Thyroid Cancer

Fineline Cube Aug 24, 2023

Eli Lilly (NYSE: LLY) has announced that its Phase III trial for the RET kinase...

Company Drug

FDA Grants Priority Review to Pfizer and Astellas’ Xtandi for High-Risk Prostate Cancer

Fineline Cube Aug 24, 2023

The US Food and Drug Administration (FDA) has granted priority review status to the submission...

Company Legal / IP

Scott-Moncrieff & Associates Preparing 50 Cases Against AstraZeneca Over Vaccine Concerns

Fineline Cube Aug 24, 2023

Scott-Moncrieff & Associates, a UK-based law firm, has disclosed that it is preparing nearly 50...

Company Drug

Nanjing F&S Pharmatech Secures First Generic Approval for Novartis’s Entresto in China

Fineline Cube Aug 24, 2023

Nanjing F&S Pharmatech Co., Ltd, a China-based pharmaceutical company, has announced that it has received...

Company

WuXi Biologics Reports 17.8% Revenue Growth and Expands Service Scope in H1 2023

Fineline Cube Aug 24, 2023

China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has released its...

Company

Johnson & Johnson Completes Spinoff of Kenvue as Independent Company

Fineline Cube Aug 24, 2023

Global healthcare giant Johnson & Johnson (J&J, NYSE: JNJ) has completed the separation of its...

Company

Everest Medicines Reports Q1 2023 Revenue Growth and Pipeline Progress

Fineline Cube Aug 24, 2023

China-based Everest Medicines (HKG: 1952) has announced its financial and corporate update for the first...

Company Drug

Lynk Pharmaceuticals’ LNK01001 Shows Positive Results in Ankylosing Spondylitis Phase II Study

Fineline Cube Aug 23, 2023

China-based Lynk Pharmaceuticals Co., Ltd has announced positive topline results from the Phase II clinical...

Company Drug

Allist Pharmaceuticals’ Furmonertinib Wins NMPA Nod for EGFR-Mutated NSCLC Treatment

Fineline Cube Aug 23, 2023

Shanghai-based Allist Pharmaceuticals Inc. (SHA: 688578) has announced that it has received clinical approval from...

Company Drug

Zai Lab’s Repotrectinib Targets Breakthrough Therapy Designation for TRK-Positive Tumors

Fineline Cube Aug 23, 2023

The Center for Drug Evaluation (CDE) website has indicated that repotrectinib, a next-generation ROS1/TRK/ALK tyrosine...

Company Deals

Hangzhou Minsheng Healthcare Aims to Raise RMB890 Million in Shenzhen GEM IPO

Fineline Cube Aug 23, 2023

Hangzhou Minsheng Healthcare Co., Ltd. (SHE: 301507) is poised to raise RMB890 million through an...

Company Drug

RemeGen’s Telitacicept Shows Positive Phase III Results in Rheumatoid Arthritis Study

Fineline Cube Aug 23, 2023

China-based RemeGen Co., Ltd (HKG: 9995, SHA: 688331) has announced positive results from the China...

Company Deals

Shanxi Jinbo Bio-pharmaceutical Plans Fundraise with Private Placement and IPO Proceeds

Fineline Cube Aug 23, 2023

China-based Shanxi Jinbo Bio-pharmaceutical Co., Ltd. (832982.BSE) is poised to raise RMB 36.75 million through...

Policy / Regulatory

CCDI Cartoon Exposes “Prescription Data Rebates” Corruption in China’s Healthcare System

Fineline Cube Aug 23, 2023

China’s Central Commission for Discipline Inspection (CCDI), the country’s anti-graft bureau, has released a cartoon...

Company Drug

Roche Subsidiary Genentech Addresses Accidental Disclosure of Tiragolumab Trial Data

Fineline Cube Aug 23, 2023

Swiss pharmaceutical major Roche (SWX: ROG), through its subsidiary Genentech, has released a statement addressing...

Policy / Regulatory

Shanghai Updates Biomedical R&D Import Pilot for Streamlined Customs Clearance

Fineline Cube Aug 23, 2023

The Shanghai Municipal Commission of Commerce, in collaboration with Shanghai Customs and the Shanghai Municipal...

Company Deals

Bayer Partners with Mahana Therapeutics to Market Digital Health Technologies

Fineline Cube Aug 23, 2023

Germany-headquartered Bayer (ETR: BAYN) has announced a strategic partnership with US digital developer Mahana Therapeutics....

Company Drug

European Commission Grants Conditional Approval for Janssen’s Talvey in Multiple Myeloma

Fineline Cube Aug 23, 2023

The European Commission (EC) has granted conditional approval to Johnson & Johnson’s (J&J; NYSE: JNJ)...

Posts pagination

1 … 428 429 430 … 610

Recent updates

  • Sino Biopharmaceutical Buys Hygieia Pharma for up to RMB 1.2 B, Adding siRNA Platform for Chronic Diseases
  • NHSA Releases NRDL Value Assessment Guidelines, Prioritizing 8 Drug Categories for Real‑World Evaluation
  • J&J’s TECVAYLI Shows 71% PFS Reduction in Phase 3 MajesTEC‑9 for Multiple Myeloma
  • Immvira Bio Files for Hong Kong IPO with Phase II Oncolytic Immunotherapy MVR-T3011
  • Exegenesis Bio Files for Hong Kong IPO with AI-Powered Gene Therapy Pipeline
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Sino Biopharmaceutical Buys Hygieia Pharma for up to RMB 1.2 B, Adding siRNA Platform for Chronic Diseases

Policy / Regulatory

NHSA Releases NRDL Value Assessment Guidelines, Prioritizing 8 Drug Categories for Real‑World Evaluation

Company Drug

J&J’s TECVAYLI Shows 71% PFS Reduction in Phase 3 MajesTEC‑9 for Multiple Myeloma

Company Deals

Immvira Bio Files for Hong Kong IPO with Phase II Oncolytic Immunotherapy MVR-T3011

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.